Healthcare Industry News: rheumatoid arthritis
News Release - January 23, 2008
Robert A. Scott, M.D., Appointed Chief Medical Officer of Cerenis TherapeuticsTOULOUSE, France and ANN ARBOR, Mich., Jan. 23 (HSMN NewsFeed) -- Cerenis Therapeutics SA, a privately held pharmaceutical company developing HDL compounds for the treatment of cardiovascular and metabolic diseases, today announced the appointment of Rob Scott, M.D., as the company's chief medical officer. Dr. Scott brings to the company more than 20 years of experience leading global cardiovascular drug development programs through clinical development to highly successful commercialization.
Most recently Dr. Scott served as executive vice president of research and development at AtheroGenics, Inc., a pharmaceutical company focused on the treatment of chronic inflammatory diseases. At AtheroGenics Dr. Scott oversaw development efforts in the areas of atherosclerosis, diabetes, rheumatoid arthritis and asthma. Previously, Dr. Scott was worldwide therapeutic head of the cardiovascular and metabolic group at Pfizer. In that role Dr. Scott was responsible for the development teams that produced: NORVASCŪ, the most- prescribed drug for high blood pressure; LIPITORŪ, the most prescribed drug for high LDL cholesterol and the world's best-selling drug; CADUETŪ, the first combination drug for the simultaneous management of two separate disease states; and other products for the treatment of diabetes and cardiac arrhythmias.
"We are honored to have Dr. Scott on board as our CMO. His deep expertise in developing novel cardiovascular treatments and his highly impressive track record in guiding blockbuster therapies through clinical development will make him a great asset to our company. For Cerenis, the appointment of Dr. Scott is a crucial step as we advance from a preclinical to a clinical development focus," said Jean-Louis Dasseux, Ph.D., President and CEO of Cerenis.
About Cerenis Therapeutics
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by the Cerenis team of world leaders in HDL therapy, the company is pursuing a range of HDL product candidates that are positioned to represent major advances in patient care and significant commercial opportunities in the treatment of cardiovascular and metabolic diseases. Cerenis has operations in Ann Arbor, Michigan and Toulouse, France. For further information please visit www.cerenis.com.
For further information, please visit www.cerenis.com.
Source: Cerenis Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.